Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Hylaton 12.5mg Tablets
⚠ This medicine appears to have been discontinued
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Chlortalidone may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
What it is and what it is used for
for Hylaton Tablets belong to a group of medicines called thiazide diuretics. Thiazide diuretics help to reduce the amount of water in your body. They do this by increasing the amount of water that you pass as urine. They are sometimes called 'water tablets'. Hylaton Tablets are used to:
- treat high blood pressure (hypertension)
- treat heart failure
- help reduce the fluid retention that occurs with some kidney or liver diseases
- treat diabetes insipidus (a condition in which an individual produces large amounts of dilute urine and is constantly thirsty).
What you need to know before you take it
e Hylaton Tablets Do not take Hylaton Tablets:
- if you are allergic to Hylaton or sulphonamides such as sulfamethoxazole or any of the other ingredients of this medicine (see Section 6. Contents of the pack and other information)
- if you are not passing any urine at all
- if you have severe kidney or liver problems
- if you have low blood levels of potassium which can cause muscle weakness, muscle twitching or abnormal heartbeat
- if you have low blood levels of sodium which can cause tiredness, confusion, muscle twitching, fits or coma
- if you have high blood levels of calcium which can cause loss of appetite, tiredness or muscle weakness
- if you have ever had gout or kidney stones
- if you have Addison's disease (which is a condition where your adrenal gland is not producing enough steroids)
- if you are taking lithium. If any of the above applies to you, or if you are not sure, speak to your doctor or pharmacist before you take Hylaton Tablets. Warnings and precautions Talk to your doctor, pharmacist or nurse before taking Hylaton Tablets:
- if you suffer from any other liver or kidney problems;
- if you are on a low-salt diet;
- if you suffer from diabetes mellitus (increased levels of sugar in the blood);
- if you have high cholesterol levels;
- if you have recently had an anaesthetic;
- if you are elderly.
- If you experience a decrease in vision or eye pain. These could be symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or an increase of pressure in your eye and can happen within hours to a week of taking Hylaton Tablets. This can lead to permanent vision loss, if not treated. If you earlier have had a penicillin or sulphonamide allergy, you can be at higher risk of developing this. If any of the above applies to you, or if you are not sure, speak to your doctor or pharmacist before you take Hylaton Tablets. Other medicines and Hylaton Tablets Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines This applies to medicinal products subject to medical prescription or those obtained without prescription, especially:
- other treatments for high blood pressure or heart problems such as:
- ACE inhibitors (for example, lisinopril)
- beta blockers (for example propranolol hydrochloride)
- methyldopa
- vasodilators (for example bosentan)
- calcium channel blockers (for example amlodipine)
- guanethidine
- corticosteroids such as prednisolone or betamethasone – used to treat allergic and inflammatory diseases and immune reactions
- adrenocorticotropic hormone (ACTH) – used to treat a number of different conditions, including ulcerative colitis (a form of inflammatory bowel disease), Crohn's disease (a form of chronic inflammatory bowel disease) and rheumatoid arthritis
- corticosteroids such as prednisolone or betamethasone – used to treat allergic and inflammatory diseases and immune reactions
- cytotoxic agents such as cyclophosphamide or methotrexate – used to treat cancer
- asthma treatments such as salbutamol or formoterol
- amphotericin – used to treat infections
- carbenoxolone – used to treat ulcers
- insulin and other treatments for diabetes such as chlorpropamide or glibenclamide
- digoxin – for an irregular heartbeat
- lithium – used to treat mental illness
- anticholinergics such as atropine sulphate or hyoscine (butylbromide) – for abdominal or stomach spasms or cramps
- colestyramine – used to reduce cholesterol levels and prevent heart disease
- amantadine – used to treat Parkinson's disease or viral infections
- allopurinol – used to treat gout (a complex type of arthritis)
- non-steroidal anti-inflammatories (NSAIDs) such as aspirin or indometacin – used for pain relief or rheumatism
- ciclosporin – used to treat rheumatic disease or skin complaints or after a transplant
- calcium salts or vitamin D – used for replacement therapy. Please tell your doctor or pharmacist if you are taking or have recently taken/used any other medicines, including medicines obtained without a prescription. Hylaton Tablets with food, drink and alcohol It is best to take Hylaton Tablets in the morning with food. Swallow your tablets whole with a drink of water. You should avoid low salt diets. Taking Hylaton Tablets may reduce the amount of salt in your body. If you are on a low salt diet check with your doctor first before taking Hylaton Tablets. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Pregnancy Do not take Hylaton Tablets if you are pregnant or trying to become pregnant. Tell your doctor, immediately, if you become pregnant during treatment with Hylaton Tablets. Breast-feeding Do not take Hylaton Tablets if you are breastfeeding because the active substance of Hylaton Tablets passes into breast milk and could harm your baby. Driving and using machines Hylaton Tablets may cause dizziness. If you feel dizzy when you start taking these tablets, do not drive or work with machinery until these effects have worn off. Hylaton Tablets contains lactose Hylaton Tablets contain a sugar called lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. Important information about Hylaton Tablets This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.
How to take it
Hylaton Tablets Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Your doctor will choose a suitable starting dose for your particular condition and monitor your progress. If necessary, this dose can be increased or reduced. Whilst you are taking Hylaton Tablets, your doctor may want to carry out a number of tests from time to time. This is quite usual and nothing to worry about. It is best to take Hylaton Tablets in the morning with food. Swallow your tablets whole with a drink of water. Adults The usual doses for adults are as follows:
- High blood pressure: The starting dose is 25 mg (half a tablet) a day. Your doctor may increase this to 50 mg (one tablet) a day if necessary.
- Heart failure: The starting dose is 25 mg (half a tablet) a day. Your doctor may increase this up to 200 mg (four tablets) a day if necessary.
- Fluid retention associated with kidney or liver disease: Up to 50 mg (one tablet) a day.
- Diabetes insipidus (a disease in which an individual produces large amounts of dilute urine and is constantly thirsty): The starting dose is 100 mg (two tablets) twice a day. Your doctor may reduce your dose to 50 mg (one tablet) a day.
Children Your doctor will choose a suitable dose based on your child's age and weight. Elderly patients or those with kidney problems Your doctor may give you a lower dose because your body may not get rid of Hylaton Tablets as quickly as normal. If you are not sure how many tablets to take, ask your doctor or pharmacist. Do not stop taking your tablets suddenly. Ask your doctor first. If you take more Hylaton Tablets than you should If you accidentally take more Hylaton Tablets than you should tell your doctor immediately or contact your nearest accident and emergency department. Show any left-over medicines or the empty packet to the doctor. If you forget to take Hylaton Tablets If you forget to take a dose, take it as soon as possible, unless it is almost time to take the next dose. Do not take a double dose. Then go on as before. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. If you get any of the following effects tell your doctor or pharmacist immediately: Very common (may affect more than 1 in 10 people):
- low blood levels of potassium which can cause muscle weakness, muscle twitching or abnormal heartbeat
- increased blood levels of uric acid
- increased blood levels of cholesterol. Common (may affect up to 1 in 10 people):
- low levels of sodium which can cause tiredness, confusion, muscle twitching, fits or coma
- low levels of magnesium
- high blood sugar levels which can cause tiredness, weakness or feeling thirsty
- nettle rash
- skin rash
- low blood pressure which may make you feel dizzy when you stand up
- dizziness
- loss of appetite
- upset stomach
- impotence in men. Rare (may affect up to 1 in 1,000 people):
- increased calcium in the blood which can cause agitation, sore eyes, abdominal pain
- sugar in the urine (this would show up when your doctor or nurse tests your urine)
- worsening of diabetes
- yellowing of the skin or eyes caused by liver or blood problems (jaundice)
- increased sensitivity of your skin to sunlight
- abnormal heartbeat the symptoms of which include palpitations and fainting
- pins and needles
- headache
- feeling or being sick
- stomach pain
- constipation
- diarrhoea
- reduction in blood platelets which increases the risk of bruising or bleeding
- severe reduction in the number of white blood cells which makes infection more likely
- an abnormally high amount of eosinophils (type of white blood cell) in the blood
- breathing problems
- problems with your kidneys.
Do not use this medicine after the expiry date which is stated on the carton or container after "EXP". The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Possible side effects
not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
How to store it
Hylaton Tablets This medicinal product does not require any special storage conditions. Keep this medicine out of the sight and reach of children. M0351LAMUKNAB1-P1-001
Contents of the pack and other information
What Hylaton Tablets contain
- The active substance is chlortalidone: Each 12.5mg Hylaton Tablet contains 12.5 mg of chlortalidone. Each 25mg Hylaton Tablet contains 25 mg of chlortalidone. Each 50mg Hylaton Tablet contains 50 mg of chlortalidone.
- The other ingredients are
- 12.5mg tablets – cellulose microcrystalline, lactose, monohydrate, povidone, sodium starch glycolate (Type A) and magnesium stearate.
- 25mg tablets – cellulose microcrystalline, lactose, monohydrate, povidone, sodium starch glycolate (Type A), yellow iron oxide (E172), red iron oxide (E172) and magnesium stearate.
- 50mg tablets – cellulose microcrystalline, lactose, monohydrate, povidone, sodium starch glycolate (Type A), yellow iron oxide (E172) and magnesium stearate. What Hylaton Tablets look like and contents of the pack Hylaton 12.5mg Tablets are white, circular and convex tablets without break line, with a diameter of 5.0 ± 0.2mm. Hylaton 25mg Tablets are pale pink to reddish, circular and convex tablets without break line, with a diameter of 7.0 ± 0.2mm. Hylaton 50mg Tablets are yellow, circular and convex tablets without break line, with a diameter of 9.0 ± 0.2mm. Hylaton Tablets are supplied in blister packs of 30 tablets. Not all pack sizes may be marketed. Marketing Authorisation Holder Morningside Healthcare Ltd. Unit C, Harcourt Way Leicester, LE19 1WP, UK Manufacturer Atlantic Pharma – Produções Farmacêuticas, S.A. Rua da Tapada Grande, n.o 2, Abrunheira 2710-089 Sintra Portugal This leaflet was last revised in September 2020.
Uncommon side effects (may affect up to 1 in 100 people)
- gout which causes pain and swelling in the joints. Very rare (may affect up to 1 in 10,000 people):
- low levels of chloride in the blood, symptoms include dry mouth, thirst, gastrointestinal disturbances (including nausea, vomiting), weakness, lethargy, drowsiness, restlessness, seizures, confusion, headache, muscle pains or cramps, hypotension
- inflammation of the pancreas which causes severe stomach and back pain. Frequency unknown:
- Decrease in vision or pain in your eyes due to high pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma). Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible
Frequently asked questions about Hylaton 12.5mg Tablets
How do I take Hylaton 12.5mg Tablets?
Hylaton 12.5mg Tablets comes as tablet containing 12.5mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
What is the active substance in Hylaton 12.5mg Tablets?
The active substance in Hylaton 12.5mg Tablets is chlortalidone.
Where does this information come from?
This leaflet reproduces the patient information leaflet approved for Hylaton 12.5mg Tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Can I get Hylaton 12.5mg Tablets without a prescription?
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
About this leaflet
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
- Source: electronic medicines compendium (emc), Datapharm
- Active substance: chlortalidone
- Official document: view the original leaflet on emc →
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
4.1. Therapeutic indications
Treatment of arterial hypertension, essential or nephrogenic or isolated systolic.
Treatment of stable, chronic heart failure of mild to moderate degree (New York Heart Association, NYHA: functional class II or III)
Oedema of specific origin
Ascites due to cirrhosis of the liver in stable patients under close control. Oedema due to nephrotic syndrome.
Diabetes Insipidus.
4.2. Posology and method of administration
Posology
The dosage of Hylaton / Chlortalidone Tablets should be individually titrated to give the lowest effective dose; this is particularly important in the elderly.
Chlortalidone should be taken orally, preferably as a single daily dose at breakfast time.
Adults:
Hypertension
The recommended starting dose is 25mg/day. This is sufficient to produce the maximum hypotensive effect in most patients. If the decrease in blood pressure proves inadequate with 25mg/day, then the dose can be increased to 50mg/day.
If a further reduction in blood pressure is required, additional hypertensive therapy may be added to the dosage regime.
Stable, chronic heart failure (NYHA: functional class II /III):
The recommended starting dose is 25 to 50mg/day. In severe cases it may be increased up to 100 -200 mg/day. The usual maintenance dose is the lowest effective dose, e.g. 25- 50 mg/day either daily or every other day. If the response proves inadequate, digitalis or an ACE inhibitor, or both, may be added. (See Section 4.4 “Special warnings and precautions for use”).
Oedema of specific origin (see Section 4.1 “Therapeutic indications”)
The lowest effective dose is to be identified by titration and administered over limited periods only. It is recommended that doses should not exceed 50mg/day.
Diabetes insipidus
Initially 100 mg twice daily but reducing where possible to a daily maintenance dose of 50 mg.
Paediatric population
The lowest effective dose should also be used in children. For example, an initial dose of 0.5 to 1 mg/kg/48hours and a maximum dose of 1.7 mg/kg/48hours have been used.
Elderly patients and patients with renal impairment:
The lowest effective dose of Hylaton /Chlortalidone Tablets is also recommended for patients with mild renal insufficiency and for elderly patients (see Section 5.2 “Pharmacokinetic properties”).
In elderly patients, the elimination of chlortalidone is slower than in healthy young adults, although absorption is the same. Therefore, a reduction in the recommended adult dosage may be needed. Close medical observation is indicated when treating patients of advanced age with chlortalidone.
Chlortalidone and the thiazide diuretics lose their diuretic effect when the creatinine clearance is <30ml/min.
4.3. Contraindications
Known hypersensitivity to chlortalidone or any of the excipients. Anuria, severe hepatic or renal failure (creatinine clearance <30ml/min), hypersensitivity to chlortalidone and other sulphonamide derivatives, refractory hypokalaemia, hyponatraemia and hypercalcaemia, symptomatic, hyperuricaemia (history of gout or uric acid calculi), hypertension during pregnancy, untreated Addison's disease and concomitant lithium therapy.
4.4. Special warnings and precautions for use
Warnings:
Hylaton / Chlortalidone Tablets should be used with caution in patients with impaired hepatic function or progressive liver disease since minor changes in the fluid and electrolyte balance due to thiazide diuretics may precipitate hepatic coma, especially in patients with liver cirrhosis (see Section 4.3 “Contra-indications”).
Chlortalidone should also be used with caution in patients with severe renal disease. Thiazides may precipitate azotaemia in such patients, and the effects of repeated administration may be cumulative.
Choroidal effusion, acute myopia and secondary angle-closure glaucoma:
Sulfonamide or sulfonamide derivative drugs can cause an idiosyncratic reaction resulting in choroidal effusion with visual field defect, transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue drug intake as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.
Precautions:
Electrolytes:
Treatment with thiazide diuretics has been associated with electrolyte disturbances such as hypokalaemia, hypomagnesaemia, hypercalcemia and hyponatraemia. Since the excretion of electrolytes is increased, a very strict low-salt diet should be avoided.
Hypokalaemia may increase the excitability of the heart or exaggerate its response to the toxic effects of digitalis.
Like all thiazide diuretics, kaluresis induced by chlortalidone is dose dependent and varies in extent from one subject to another. With 25 to 50 mg/day, the decrease in serum potassium concentrations averages 0.5mmol/l.
Periodic serum electrolyte determinations should be carried out, particularly in digitalised patients.
If necessary, Hylaton / Chlortalidone Tablets may be combined with oral potassium supplements or with a potassium- sparing diuretic (e.g. triamterene).
If hypokalaemia is accompanied by clinical signs (e.g. muscular weakness, paresis and ECG alteration), Hylaton / Chlortalidone Tablets should be discontinued.
Combined treatment consisting of Hylaton / Chlortalidone Tablets and a potassium salt or a potassium-sparing diuretic should be avoided in patients treated with ACE inhibitors.
Monitoring of serum electrolytes is particularly indicated in the elderly, in patients with ascites due to liver cirrhosis, and in patients with oedema due to nephrotic syndrome. There have been isolated reports of hyponatraemia with neurological symptoms (e.g. nausea, debility, progressive disorientation and apathy) following thiazide treatment.
For nephrotic syndrome, chlortalidone should be used only under close control in normokalaemic patients with no signs of volume depletion.
Metabolic effects:
Chlortalidone may raise the serum uric acid level, but attacks of gout are uncommon during chronic treatment.
As with the use of other thiazide diuretics, glucose intolerance may occur; this is manifest as hyperglycaemia and glycosuria. Chlortalidone may very seldom aggravate or precipitate diabetes mellitus; this is usually reversible on stopping therapy.
Small and partly reversible increases in plasma concentrations of total cholesterol, triglycerides, or low- density lipoprotein cholesterol were reported in patients during long-term treatment with thiazides and thiazide-like diuretics. The clinical relevance of these findings is a matter for debate.
Hylaton / Chlortalidone Tablets should not be used as a first-line drug for long-term treatment in patients with overt diabetes mellitus or in subjects receiving therapy for hypercholesterolaemia (diet or combined).
As with all antihypertensive agents, a cautious dosage schedule is indicated in patients with severe coronary or cerebral arteriosclerosis.
Other effects:
The antihypertensive effect of ACE inhibitors is potentiated by agents that increase plasma renin activity (diuretics). It is recommended that the diuretic be reduced in dosage or withdrawn for 2 to 3 days and/or that the ACE inhibitor therapy be started with a low initial dose of the ACE inhibitor. Patients should be monitored for several hours after the first dose.
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
4.5. Interaction with other medicinal products and other forms of interaction
Diuretics potentiate the action of curare derivatives and antihypertensive drugs (e.g. guanethidine, methyldopa, β-blockers, vasodilators, calcium antagonists and ACE inhibitors).
The hypokalaemic effect of diuretics may be potentiated by corticosteroids, ACTH, ß2 – agonists, amphotericin and carbenoxolone.
It may prove necessary to adjust the dosage of insulin and oral anti-diabetic agents.
Thiazide-induced hypokalaemia or hypomagnesaemia may favour the occurrence of digitalis-induced cardiac arrhythmias (see Section 4.4 “Special warnings and precautions for use”).
Concomitant administration of certain non-steroidal anti-inflammatory drugs (e.g. indometacin) may reduce the diuretic and antihypertensive activity of chlortalidone; there have been isolated reports of a deterioration in renal function in predisposed patients.
The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g. atropine, biperiden), apparently due to a decrease in gastrointestinal motility and stomach-emptying rate.
Absorption of thiazide diuretics is impaired in the presence of anionic exchange resins such as colestyramine. A decrease in the pharmacological effect may be expected.
Concurrent administration of thiazide diuretics may increase the incidence of hypersensitivity reactions to allopurinol, increase the risk of adverse effects caused by amantadine, enhance the hyperglycaemic effect of diazoxide, and reduce renal excretion of cytotoxic agents (e.g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.
The pharmacological effects of both calcium salts and vitamin D may be increased to clinically significant levels if given with thiazide diuretics. The resultant hypercalcaemia is usually transient but may be persistent and symptomatic (weakness, fatigue, anorexia) in patients with hyperparathyroidism.
Concomitant treatment with cyclosporin may increase the risk of hyperuricaemia and gout-type complications.
Thiazide and related diuretics can cause a rapid rise in serum lithium levels as the renal clearance of lithium is reduced by these compounds.
4.6. Fertility, pregnancy and lactation
Pregnancy
Diuretics are best avoided for the management of oedema or hypertension in pregnancy as their use may be associated with hypovolaemia, increased blood viscosity and reduced placental perfusion. There have been reports of foetal bone marrow depression, thrombocytopenia, and foetal and neonatal jaundice associated with the use of thiazide diuretics.
Breastfeeding
Chlortalidone passes into the breast milk; mothers taking chlortalidone should refrain from breast-feeding their infants.
4.7. Effects on ability to drive and use machines
Patients should be warned of the potential hazards of driving or operating machinery if they experience side effects such as dizziness.
4.8. Undesirable effects
Frequency estimate: very rare <0.01%, rare ≤0.01% to ≤0.1%; uncommon ≤0.1% to <1%; common ≤1% to <10%; very common ≥10%.
Electrolytes and metabolic disorders:
Very common: mainly at higher doses, hypokalaemia, hyperuricaemia, and rise in blood lipids.
Common: hyponatraemia, hypomagnesaemia and hyperglycaemia.
Uncommon: gout.
Rare: hypercalcaemia, glycosuria, worsening of diabetic metabolic state.
Very rare: hypochloraemic alkalosis.
Skin:
Common: urticaria and other forms of skin rash.
Rare: photosensitisation.
Liver
Rare: intrahepatic cholestasis or jaundice.
Cardiovascular system:
Common: postural hypotension.
Rare: cardiac arrhythmias.
Central nervous system:
Common: Dizziness.
Rare: paraesthesia, headache.
Gastro-intestinal tract;
Common: loss of appetite and minor gastrointestinal distress.
Rare: mild nausea and vomiting, gastric pain, constipation and diarrhoea.
Very rare: pancreatitis.
Blood:
Rare: Thrombocytopenia, leucopenia, agranulocytosis and eosinophilia.
Eye disorders:
Frequecncy unknown: choroidal effusion
Other effects:
Common: impotence
Rare: Idiosyncratic pulmonary oedema (respiratory disorders), allergic interstitial nephritis.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9. Overdose
Signs and symptoms
In poisoning due to an overdosage the following signs and symptoms may occur: dizziness, nausea, somnolence, hypovolaemia, hypotension and electrolyte disturbances associated with cardiac arrhythmias and muscle spasms.
Treatment
There is no specific antidote to chlortalidone. Gastric lavage, emesis or activated charcoal should be employed to reduce absorption. Blood pressure and fluid and electrolyte balance should be monitored and appropriate corrective measures taken Intravenous fluid and electrolyte replacement may be indicated.
🇷🇴 Known in Romania as
Medicines sold in Romania with the same active substance: Cunoscut în România ca
- ULDIULAN 12,5 mg prescriptionCHLORTALIDONUM · taken by mouth
- ULDIULAN 25 mg prescriptionCHLORTALIDONUM · taken by mouth
- ULDIULAN 50 mg prescriptionCHLORTALIDONUM · taken by mouth
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
🇵🇱 Known in Poland as
Medicines sold in Poland with the same active substance: W Polsce znany jako
- HygrotonChlortalidonum · taken by mouth
- UldiulanChlortalidonum · taken by mouth
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
💬 Ask about this leaflet
Ask anything about Hylaton 12.5mg Tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.